The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study to assess pharmacokinetics (PK), QT/QTc effect, and safety of amrubicin in patients (pts) with advanced solid tumors.
N. Chen
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
S. P. Chawla
Research Funding - Celgene
E. G. Chiorean
Research Funding - Celgene
W. L. Read
Research Funding - Celgene
M. Gorbaty
No relevant relationships to disclose
A. C. Mita
No relevant relationships to disclose
L. Yung
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
R. McNally
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
M. F. Renschler
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
S. Sharma
Research Funding - Celgene